Last $159.11 USD
Change Today +0.45 / 0.28%
Volume 740.1K
SLXP On Other Exchanges
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/14 - $162.38
52 Week Low
09/6/13 - $65.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $488.9K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (SLXP) Key Developments

Pharming Group NV and Salix Pharmaceuticals Ltd. Announces the Initiation of Clinical Study of RUCONEST

Pharming Group NV and Salix Pharmaceuticals Ltd. announced the initiation of a clinical study of RUCONEST(Registered), (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, for attack prophylaxis in patients with hereditary angioedema (HAE). The phase 2 randomized, double-blind, placebo-controlled, crossover study will evaluate the safety and efficacy of RUCONEST(Registered) when used for the prophylaxis of angioedema attacks in patients with HAE. The study will enroll approximately 30 patients and compare a dosing regimen of RUCONEST(Registered) given either once or twice weekly versus placebo over a total of 12 weeks. The initiation of the study follows the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The study will be conducted at sites in Europe and the United States. Under the terms of the Pharming-Salix license agreement, the companies will equally share the development costs for RUCONEST(Registered) for HAE prophylaxis and Pharming will receive an undisclosed milestone payment from Salix at FDA approval for this additional indication. This randomized-controlled study follows an open-label study with RUCONEST(Registered) given once weekly, which was published in the peer reviewed journal Allergy in November 2012. The 25 patients included in the open-label study had a history of frequent HAE attacks (mean 0.9 attacks/week). During the 8 week RUCONEST(Registered) treatment period, the mean frequency of HAE attacks was reduced by more than 50% to 0.4 attacks/week. The repeated administrations were generally safe and well-tolerated. The results of that open-label study suggest that RUCONEST(Registered) could be effective in providing long term prophylaxis in patients with frequent attacks.

Allergan Reportedly Approached Salix For Acquisitions

Allergan Inc. (NYSE:AGN) has reportedly approached Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP) and at least one other company about a potential acquisition, as Allergan seeks to fend off a $53-billion hostile takeover from Valeant Pharmaceuticals International, Inc. (TSX:VRX). Allergan could strike a takeover deal with the company or another unknown party as early as next month, September 2014. Allergan has said it is eyeing acquisitions of its own.

Levi & Korsinsky Notifies Investors of Salix Pharmaceuticals Ltd. of Class Action Against its Board Of Directors in Connection with the Sale Of the Company to Cosmo Tech

Levi & Korsinsky notified to the investors of Salix Pharmaceuticals Ltd. of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the company to Cosmo Tech, a subsidiary of Cosmo Pharmaceuticals S.p. A which will change its name to Salix Pharmaceuticals, plc upon the completion of the merger. A complaint was filed in Delaware state court. Under the terms of the transaction, Salix shareholders will receive one share of the post-merger entity for each share of Salix they own. Salix shareholders will own 80% of the newly combined company. The claims concern whether the Board of Salix breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cosmo Pharmaceuticals S.p.A. is underpaying for Salix shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $159.11 USD +0.45

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.73 USD +0.25
Cubist Pharmaceuticals Inc $69.03 USD +0.12
Jazz Pharmaceuticals PLC $162.92 USD +0.21
Lupin Ltd 1,285 INR -4.25
Santen Pharmaceutical Co Ltd ¥6,000 JPY -110.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SLXP Industry Range
Price/Earnings 100.0x
Price/Sales 8.0x
Price/Book 13.7x
Price/Cash Flow 53.0x
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at